You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Article metrics

Article menu

Download PDFPDF

XML
Basic tumor immunology
Original research
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

 

Online download statistics by month:

Online download statistics by month: April 2020 to August 2024

AbstractFullPdf
Apr 2020728728403
May 2020742742385
Jun 2020284284104
Jul 2020320320153
Aug 202024024085
Sep 2020292292129
Oct 202017417487
Nov 2020192192104
Dec 202016216271
Jan 2021275275162
Feb 2021362362119
Mar 2021302302140
Apr 2021294294130
May 2021216216131
Jun 2021211211139
Jul 202120720795
Aug 202119819897
Sep 2021195195103
Oct 2021198198113
Nov 2021250248154
Dec 2021237238100
Jan 2022252262130
Feb 202215716493
Mar 2022258260129
Apr 202220522297
May 2022261261128
Jun 202221621988
Jul 2022220232131
Aug 2022225233134
Sep 2022291299102
Oct 2022293298107
Nov 202232232888
Dec 202224724863
Jan 202323924268
Feb 202326226293
Mar 202323223673
Apr 202319819962
May 202325425472
Jun 202321021038
Jul 202322223178
Aug 202314814941
Sep 202317317356
Oct 202316016048
Nov 202316116161
Dec 202327327364
Jan 202411511658
Feb 202414914949
Mar 2024206207120
Apr 202413813858
May 202411411767
Jun 202410710857
Jul 202416316656
Aug 2024134133132
Total12684127885645